Avalo Therapeutics (AVTX) Accumulated Depreciation (2014 - 2015)
Avalo Therapeutics posted quarterly Accumulated Depreciation of $60835.0 for Q4 2015, up 62.97% year-on-year from $37328.0 in Q4 2014, and up 62.97% on a QoQ basis from $37328.0 in Q4 2014.
Avalo Therapeutics (AVTX) has 2 years of Accumulated Depreciation data on file, last reported at $60835.0 in Q4 2015.
- For the quarter ending Q4 2015, Accumulated Depreciation rose 62.97% year-over-year to $60835.0; the trailing twelve-month figure through Dec 2015 stood at $60835.0 (up 62.97% YoY), and the FY2015 full-year result was $60835.0, up 62.97% from the prior year.
- Accumulated Depreciation for Q4 2015 stood at $60835.0, up from $37328.0 in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $60835.0 in Q4 2015 and bottomed at $37328.0 in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 60,835.00 |
| Dec 31, 2014 | 37,328.00 |